DES was found to be more effective than androgens in the treatment of advanced breast cancer in postmenopausal women. [ 18 ] DES was the hormonal treatment of choice for advanced breast cancer in postmenopausal women until 1977, when the FDA approved tamoxifen , a selective estrogen receptor modulator with efficacy similar to DES but fewer side effects